Paul Wallace
Director/Board Member at Stroma Biosciences Ltd.
Paul Wallace active positions
Companies | Position | Start | End |
---|---|---|---|
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | Director/Board Member | 31/12/2020 | - |
Career history of Paul Wallace
Former positions of Paul Wallace
Companies | Position | Start | End |
---|---|---|---|
MEDIVIR AB | Corporate Officer/Principal | 31/12/1999 | 27/02/2015 |
Training of Paul Wallace
University of Cambridge | Doctorate Degree |
Statistics
International
United Kingdom | 3 |
Sweden | 2 |
Operational
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Director/Board Member | 1 |
Sectoral
Health Technology | 2 |
Consumer Services | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
MEDIVIR AB | Health Technology |
Private companies | 1 |
---|---|
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | Commercial Services |
- Stock Market
- Insiders
- Paul Wallace
- Experience